Advertisement
Screener

LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share

LIGAND PHARMACEUTICALS INCORPORATED Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share

LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share of -$0.08 per share for the 3-month period ending 2013-12-31, per its 10-K filed 2014-12-01.

Discontinued › Income Statement › Net Income

us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare · last filed 2014-12-12

  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2013-12-31 was -$0.08.
  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2013-09-30 was $0.00.
  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2013-06-30 was $0.09, a 0.00% change year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2013-03-31 was $0.10, a 0.00% change year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2012 was $0.11.
  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2010 was $0.12, a 64.71% decline from fiscal 2009.
  • LIGAND PHARMACEUTICALS INCORPORATED income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2009 was $0.34.
Period endIncome (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 3 monthIncome (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 3 month as first filedIncome (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 6 monthIncome (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 9 monthIncome (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month
2013-12-31-$0.08
10-K · filed 2014-12-01
2013-09-30$0.00
10-K · filed 2014-12-01
2013-06-30$0.09
10-K · filed 2014-12-01
2013-03-31$0.10
10-K · filed 2014-12-01
$0.01
10-Q · filed 2013-05-08
2012-12-31-$0.08
10-K/A · filed 2014-12-12
$0.11
10-K · filed 2013-03-14
2012-09-30$0.00
10-K/A · filed 2014-12-12
$0.19
10-Q · filed 2012-11-14
2012-06-30$0.09
10-K/A · filed 2014-12-12
$0.19
10-Q/A · filed 2012-11-14
2012-03-31$0.10
10-K/A · filed 2014-12-12
2011-06-30$0.00
10-Q · filed 2012-08-08
$0.00
10-Q · filed 2012-08-08
2011-03-31$0.00
10-Q · filed 2012-05-04
2010-12-31$0.12
10-K · filed 2013-03-14
2010-09-30$0.01
10-Q/A · filed 2012-02-10
2010-06-30$0.00
10-Q/A · filed 2012-02-10
$0.01
10-Q/A · filed 2012-02-10
2009-12-31$0.34
10-K/A · filed 2012-11-14